Deals of the week: Transplant Genomics, Prosetta Biosciences, Orchard Therapeutics

5th May 2016 (Last Updated May 5th, 2016 18:30)

Transplant Genomics and Astellas Pharma have entered a partnership to further develop laboratory services and clinical trials for renal transplant patients.

University College London

Transplant Genomics and Astellas Pharma have entered a partnership to further develop laboratory services and clinical trials for renal transplant patients.

Pursuant to the agreement, Astellas will be responsible for funding and providing blood samples of renal transplant patients and Transplant Genomics will be responsible for real-time molecular analysis of blood samples to measure molecular signatures of immune activation in renal transplant patients.

The blood samples were collected during the two-year, prospective, randomised, multi-centre clinical trials using Transplant Genomics TruGraf test.

Prosetta Biosciences and Takeda Pharma will jointly discover and develop novel drugs for neurodegenerative diseases, as part of a feasibility and first right negotiation agreement between the two companies.

The agreement allows both companies to perform initial and planned research, as well as carry out R&D related to target of interest with a separate comprehensive collaboration and license option agreement.

According to the agreement, Prosetta Biosciences will receive upfront payments, pre-commercialisation, commercialisation milestones and royalty payments on marketed products from Takeda Pharma.

Orchard Therapeutics, a clinical-stage biotechnology company, has raised $30.73m funds in a Series A financing round.

The financing was led by F-Prime Capital Partners with the support of UCL Business PLC and UCL Technology Fund.

The company intends to use the funds to develop transformative gene therapies for orphan diseases along with its partners University College of London (UCL), Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), University of Manchester, University of California Los Angeles (UCLA) and Boston Children Hospital under a co-development agreement.

Homology Medicines plans to further develop gene editing technology using the funds raised from the recently concluded Series A financing round.

"The company plans to invest the funds in the clinical development of VT-1161, research and development of VT-1129, VT-1598, general corporate purposes."

The company has raised approximately $43.5m from the financing round, which was led by 5AM Venture management, ARCH Venture Partners with the support of Temasek Holdings, Deerfield Management and ARCH Overage Fund.

Viamet Pharma has announced that it will raise funds amounting from $79.8m to $91.2m through the initial public offering (IPO) of its 5,700,000 common stock shares at a price range of $14 to $16 per share.

The company has further announced that it has granted a 30-day option to buy up to 855,000 additional shares to its underwriters, namely Morgan Stanley, Goldman & Sachs, Guggenheim Securities and Needham & Company.

The company plans to invest the funds in the clinical development of VT-1161, research and development of VT-1129, VT-1598, general corporate purposes and also to invest in capital preservation investments, which include short-term, investment-grade and interest-bearing instruments, and US government securities.


Image: Orchard Therapeutics has entered a co-development agreement with University College of London (UCL). Photo: Courtesy of Steve Cadman.